



Food and Drug Administration
Rockville MD 20857

3533 03 11 20 19:37

Re: Factive
Docket Nos. 03E-0449
03E-0411
03E-0448

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

NOV 18 2003

Dear Director Rogan:

This is in regard to the applications for patent term extension for U.S. Patent Nos. 5,962,468; 5,633,262; and 5,776,944 filed by LG Life Sciences under 35 U.S.C. § 156. The human drug product claimed by the patents is Factive (gemifloxacin mesylate), which was assigned NDA No. 21-158.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The NDA was approved on April 4, 2003, which makes the submission of the three patent term extension applications on May 29, 2003, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patents are eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Charles E. Van Horn
Finnegan, Henderson, Farabow, Garrett & Dunner
1300 Eye Street, NW
Washington, DC 20005-3315

03E-0411

LET 2